Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors.

In the 4-week landmark analysis, although the survival advantage of GI-irAEs in the PNI ≥ 40 group did not reach statistical significance, a similar ordering was observed, with patients experiencing GI-irAEs showing the most favorable outcomes, followed by those with non-GI irAEs and those without irAEs ( Figure 2 D).

also in 111,027 other papers